Publicaciones en colaboración con investigadores/as de University of Oklahoma (11)

2024

  1. Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe

    International Journal of Gynecological Cancer

  2. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

2021

  1. Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004))

    Annals of Oncology

  2. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 632-642

  3. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

    Gynecologic Oncology, Vol. 163, Núm. 1, pp. 41-49

2020

  1. Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial

    Journal of Clinical Oncology, Vol. 38, Núm. 30, pp. 3528-3537

  2. First-line PARP inhibitors in ovarian cancer: Summary of an ESMO Open - Cancer Horizons round-table discussion

    ESMO Open, Vol. 5, Núm. 6

  3. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1148-1159

2019

  1. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial

    Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2825-2834

2018

  1. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 379, Núm. 26, pp. 2495-2505